Molicotti Paola, Ortu Silvia, Bua Alessandra, Cannas Sara, Sechi Leonardo A, Zanetti Stefania
Department of Biomedical Sciences, Institute of Microbiology, University of Sassari, Italy.
New Microbiol. 2006 Oct;29(4):275-80.
Linezolid, an oxazolidinone that acts by inhibiting protein synthesis, was evaluated in strains of tuberculosis and non-tubercular mycobacteria resistant to one or more drugs isolated in northern Sardinia. The in vitro activity of Linezolid (Pfizer) was assessed on different isolates of Mycobacterium spp. from clinical samples by the Proportional Method. Linezolid demonstrated an excellent activity against the 24 strains of M. tuberculosis and against M. gordonae, M. marinum, M. aurum, M. phlei, and M. avium, with MIC values ranging from 0.5 to 2 microg/ml. Linezolid can be used in combination with the standard antitubercular medications, or as an effective therapeutic alternative in infections caused by M. tuberculosis or by other species of non-tubercular mycobacteria.
利奈唑胺是一种通过抑制蛋白质合成发挥作用的恶唑烷酮，对在撒丁岛北部分离出的对一种或多种药物耐药的结核分枝杆菌和非结核分枝杆菌菌株进行了评估。采用比例法对来自临床样本的不同分枝杆菌属分离株评估了利奈唑胺（辉瑞公司生产）的体外活性。利奈唑胺对24株结核分枝杆菌以及戈登分枝杆菌、海分枝杆菌、金分枝杆菌、草分枝杆菌和鸟分枝杆菌表现出优异的活性，其最低抑菌浓度值范围为0.5至2微克/毫升。利奈唑胺可与标准抗结核药物联合使用，或作为治疗由结核分枝杆菌或其他非结核分枝杆菌引起的感染的有效治疗选择。
